Home › Stocks › AMLX › All Fund Holders
AMLX — AMYLYX PHARMACEUTICALS INC · All Fund Holders
Funds holding (latest): 40 · Reported value held: $995.92M
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Fidelity Management & Research (FMR) history | Q2 2026 | 16.73M | $300.43M | 0.01% | Add |
| BlackRock Inc history | Q2 2026 | 8.83M | $158.53M | 0.00% | Hold |
| Vanguard Group history | Q4 2025 | 5.80M | $70.12M | 0.00% | Add |
| Janus Henderson Group history | Q1 2026 | 4.99M | $69.26M | 0.03% | Add |
| Morgan Stanley history | Q2 2026 | 3.13M | $56.23M | 0.00% | Add |
| Franklin Resources history | Q2 2026 | 2.95M | $52.99M | 0.01% | Add |
| Goldman Sachs Group history | Q2 2026 | 2.86M | $51.33M | 0.01% | Add |
| Viking Global Investors history | Q4 2023 | 2.96M | $43.61M | 0.16% | Hold |
| Geode Capital Management history | Q2 2026 | 2.34M | $41.95M | 0.00% | Add |
| JPMorgan Chase & Co history | Q2 2026 | 1.86M | $34.92M | 0.00% | New |
| Northern Trust Corp history | Q2 2026 | 831.74K | $14.94M | 0.00% | Add |
| Bank of America Corp history | Q2 2026 | 821.84K | $14.76M | 0.00% | Reduce |
| Charles Schwab Investment Management history | Q2 2026 | 725.03K | $13.02M | 0.00% | Add |
| Balyasny Asset Management history | Q2 2026 | 684.97K | $12.30M | 0.02% | Reduce |
| Two Sigma Investments history | Q2 2026 | 593.43K | $10.66M | 0.01% | Add |
| Deutsche Bank AG history | Q2 2026 | 557.94K | $10.02M | 0.00% | Reduce |
| BNY Mellon history | Q2 2026 | 274.44K | $4.93M | 0.00% | Add |
| UBS Group AG history | Q2 2026 | 271.88K | $4.88M | 0.00% | Reduce |
| Wellington Management Group history | Q2 2026 | 212.84K | $3.82M | 0.00% | Reduce |
| Farallon Capital Management history | Q3 2024 | 1.15M | $3.73M | 0.02% | Hold |
| Citadel Advisors history | Q2 2026 | 189.39K | $3.40M | 0.00% | Reduce |
| D. E. Shaw & Co history | Q2 2026 | 174.28K | $3.13M | 0.00% | Add |
| Norges Bank Investment Management history | Q2 2026 | 159.90K | $2.87M | 0.00% | New |
| Invesco Ltd history | Q2 2026 | 139.94K | $2.51M | 0.00% | Reduce |
| Renaissance Technologies history | Q4 2025 | 192.50K | $2.33M | 0.00% | Add |
| Wells Fargo & Co history | Q2 2026 | 128.16K | $2.30M | 0.00% | Add |
| Citigroup Inc history | Q2 2026 | 68.68K | $1.23M | 0.00% | Add |
| Legal & General Investment Management America history | Q2 2026 | 56.48K | $1.01M | 0.00% | Add |
| Marshall Wace history | Q1 2025 | 247.28K | $875.35K | 0.00% | Add |
| Moore Capital Management history | Q3 2023 | 47.08K | $862.00K | 0.02% | New |
| Manulife Financial history | Q2 2026 | 37.83K | $679.39K | 0.00% | Reduce |
| Millennium Management history | Q4 2025 | 46.45K | $561.18K | 0.00% | Reduce |
| CPP Investments history | Q2 2026 | 27.60K | $495.70K | 0.00% | New |
| AQR Capital Management history | Q2 2026 | 20.82K | $373.91K | 0.00% | Reduce |
| Point72 Asset Management history | Q2 2026 | 15.80K | $283.77K | 0.00% | Reduce |
| Prudential Financial history | Q2 2026 | 15.11K | $271.38K | 0.00% | Add |
| Amundi US history | Q2 2026 | 12.89K | $231.59K | 0.00% | Hold |
| Principal Global Investors history | Q1 2024 | 14.67K | $41.65K | 0.00% | Add |
| PNC Financial Services history | Q2 2026 | 406 | $7.29K | 0.00% | Add |
| T. Rowe Price Associates history | Q2 2026 | 145.13K | $2.61K | 0.00% | Add |